Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s weight-loss and diabetes drugs, Zepbound and Mounjaro. The drop occurred after President Donald Trump suggested that the price for the GLP-1 drug category, which Eli Lilly dominates alongside…
Since its initial synthesis by the German pharmaceutical company Merck in 1912, the drug 3,4-methylenedioxy-methylamphetamine (MDMA) — better known by the street terms “ecstasy” or “molly” — has lived many lives. From its brief time being tested as a top-secret truth serum in US Army trials to its dual uses as a therapeutic tool and party…
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 13.9% in the afternoon session after its oral weight-loss drug trial results disappointed investors, overshadowing an otherwise strong quarterly earnings report and guidance increase. The pharmaceutical company announced late-stage trial data for its oral weight-loss pill, orforglipron, which showed an average weight loss of 12.4%. This…
As the U.S. stock market experiences fluctuations with major indices like the Dow Jones and S&P 500 retreating from early-session gains, investors are increasingly focused on companies with strong fundamentals amid concerns over tariffs and economic outlooks. In this environment, growth companies with high insider ownership can be particularly appealing, as insider confidence often signals…